PYXS

Pyxis Oncology, Inc. operates as a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Headquartered in Boston, Massachusetts, the company concentrates on creating antibody-drug conjugates (ADCs) and immunological agents designed to treat difficult-to-treat cancers. Pyxis's pipeline includes several product candidates in various stages of development, with its lead program, PYX-201, an ADC targeting solid tumors that express the B7-H3 antigen. The company also develops PYX-106, an anti-Siglec-15 antibody designed to overcome immune suppression in the tumor microenvironment, and PYX-335, a next-generation ADC platform. Pyxis emerged as an independent entity following its separation from Apexigen, Inc. in 2021 and completed its initial public offering in March 2022. The company partners with multiple research institutions and pharmaceutical organizations to advance its clinical programs and expand its therapeutic pipeline. As a development-stage enterprise, Pyxis generates no product revenue and focuses its resources on research and development activities, clinical trial execution, and regulatory advancement of its oncology candidates. The company maintains its operations primarily in the United States and conducts clinical trials at various sites globally to evaluate the safety and efficacy of its investigational therapies in patients with advanced cancers.